Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole   increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 12/February/2018, 12.09 am

Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Lansoprazole (LP)  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 11/February/2018, 11.56 pm
February 11, 2018
Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing AM-1241, DH4O4 and-DL-3n-Butylphthalide decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 12/February/2018, 12.33 am
February 11, 2018
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole   increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene


From significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to Therapeutic opportunity: 

This study provides, for the first time, mechanistic insights into how a pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole may protect against cardiovascular diseases.

 The pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole, by decreasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration.  

Figure1. Mechanistic insights into how a pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole  may promote cardiac dedifferentiation and regeneration. The pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole, by increasing the expression of its target gene, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

Figure 2. The chemical structure of a pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole. The pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole may promote cardiac regeneration through induction of Her2/Erbb2

Thus, pharmacological formulations encompassing “Pyridoxamine and Omeprazole  or their analogues, either alone or in combination with other drugs “ may be used to promote cardiomyocyte regeneration following myocardial infarction


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How  a pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole increases the expression of  ERBB2/Her2

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole   increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 12/February/2018, 12.09 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.